Markov diagram of health states and the possible transitions among them during each 1-month cycle.

<p>Markov diagram of health states and the possible transitions among them during each 1-month cycle.</p

A tornado diagram of one-way uncertainty analyses in the overall cohort.

<p>The graph shows the effects of the variables on net health benefit (in QALYs, with WTP = 11,034) between the RT and TMZ strategies. The width of the bars represents the range of the results when the variables are changed, as shown in Tables 1, 2, 3. The vertical dotted line represents the base-case results. The vertical line represents the base-case value for the net health benefit with WTP = 11,034. PFS: progression-free survival; OS: overall survival; HR: hazard ratio.</p

Analysis of the cost effectiveness of the first-line strategies for GBM in the overall cohort and the 8 subgroups.

<p>The x-axis represents the undiscounted 5-year quality-adjusted life-years (QALYs) for each strategy, and the y-axis represents the total undiscounted 5-year costs (in US dollars). The oblique line connects the RT strategy and the most cost-effective strategies; strategies above the straight lines were dominated or extended dominated.</p

Base Case Results for the Alternative Strategies for Cost, QALY Gained and ICER.

<p>Base Case Results for the Alternative Strategies for Cost, QALY Gained and ICER.</p

Trial Data and Model Estimated Values.

<p>NA: not applicable.</p

The cost-effectiveness acceptability curves for the three first-line strategies for GBM in the overall cohort and the 8 subgroups.

<p>The vertical axes represent the probabilities of cost effectiveness. The horizontal axes represent the willingness-to-pay thresholds to gain 1 additional quality-adjusted life-year (QALY). The bold vertical dashed and solid lines represent the thresholds for China and Shanghai City, respectively.</p

The probabilistic results of the incremental cost-utility differences for GBM in the overall cohort and the 8 subgroups.

<p>The TMZ strategy was compared to: (A) the RT strategy and (B) the NT strategy for a cohort of 1,000 GBM patients. The y-axis represents the incremental costs. The x-axis represents the incremental QALYs gained. Each ellipse represents the 95% confidence interval ellipse of the probabilistic results. The proportion of the ellipses found below the ICER threshold (the oblique lines) reflects the simulations in which the cost per additional QALY gained with the TMZ strategy was below the ICER threshold.</p

Table1_Genetic variant of ADH1C for predicting survival in esophageal squamous cell cancer patients who underwent postoperative radiotherapy.docx

Background: Single nucleotide polymorphisms (SNPs) of essential enzymes for alcohol metabolism ADH1B, ADH1C, and ALDH2 are commonly regarded as genetic biomarkers for esophageal squamous cell carcinoma (ESCC) susceptibility. However, there have not been any reports on relations between SNPs of these genes and the prognosis of postoperative radiotherapy in ESCC. The current study aimed to understand the associations between gene variants of alcohol metabolism and adjuvant radiotherapy’s prognosis in ESCC.Methods: This study retrospectively analyzed 110 ESCC patients from our institution who received adjuvant radiotherapy after surgery. The SNPs of ADH1B rs1229984, ADH1C rs1789924, and ALDH2 rs671 were detected by Sanger sequencing using formalin-fixed paraffin-embedded tumor samples. A nomogram was drawn based on prognostic factors associated with overall survival (OS).Results: ADH1C rs1789924 (C>T) was associated with poor DFS and OS in ESCC patients undergoing adjuvant radiotherapy. Multivariate analysis showed that ADH1C rs1789924 (C>T) was one of the independent prognosis factors of DFS and OS. However, the genotypes of ADH1B SNP rs1229984 and ALDH2 rs671 were not associated with differences in the PFS and OS of these patients. Compared with the AJCC staging system, the nomogram containing the ADH1C genotype can more effectively and accurately predict the survival time of ESCC after surgery and adjuvant radiotherapy.Conclusion: ADH1C rs1789924 might be a prognostic genetic biomarker for ESCC patients undergoing surgery and postoperative radiotherapy.</p